Market Snapshot
S&P Futures
3,819
Dow Futures
30,822
Nasdaq Futures
11,785
Acumen Pharmaceuticals, Inc. (ABOS) stock rallied over 15.79% intraday to trade at $5.50 a share on NASDAQ. The stock opened with a gain of 18.28% at $4.75 and touched an intraday high of $5.5, rising 15.79% against the last close of $4.75. The stock went to a low of $4.659 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-07-06 | $4.75 | $5.5 | $4.659 | $5.5 | 113,384 |
2022-07-05 | $4.65 | $4.933 | $4.55 | $4.75 | 128,200 |
2022-07-01 | $4.71 | $5.023 | $4.401 | $4.71 | 114,100 |
2022-06-30 | $4.92 | $5.03 | $4.62 | $4.7 | 225,900 |
2022-06-29 | $4.4 | $5.025 | $4.34 | $4.88 | 239,700 |
2022-06-28 | $4.09 | $4.46 | $3.96 | $4.39 | 158,400 |
2022-06-27 | $3.78 | $4.16 | $3.64 | $4.1 | 286,300 |
2022-06-24 | $3.71 | $3.92 | $3.44 | $3.75 | 3,362,100 |
2022-06-23 | $3.45 | $3.69 | $3.44 | $3.69 | 224,100 |
2022-06-22 | $3.32 | $3.69 | $3.31 | $3.46 | 320,100 |
Employees-
Beta-
Sales or Revenue0
5Y Sales Change-
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryBiotechnology
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) stock price is $5.5 as of the last check on Wednesday, July 6. During the trading session, ABOS stock reached the peak price of $5.5 while $4.659 was the lowest point it dropped to.
The NASDAQ listed ABOS is part of Biotechnology industry that operates in the broader Health Care sector. Acumen Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease.
Mr. Matt Zuga
CFO & Chief Bus. Officer
Ms. Robyn Moxon M.A.
Mang. of Corp. & Clinical Communications
Ms. Julie Bockenstette
Exec. VP & Head of HR
Ms. Janice Hitchcock
VP & Head of Regulatory Affairs
ABOS stock traded closed the last session at $5.5, which is $0.75 or 15.79% lower than its previous close of $4.75. ABOS's current trading price is 82.12% lower than its 52-week high of $20.59 where as its distance from 52-week low of 3.02% is -73.29%.
Number of ABOS employees currently stands at -. ABOS operates from 427 Park St., Charlottesville, VA 22902, United States.
Official Webiste of $ABOS is: https://www.acumenpharm.com
ABOS could be contacted at ABOS operates from 427 Park St., Charlottesville, VA 22902, United States, or at phone #434 297 1000 and can also be accessed through its website.
ABOS stock volume for the day was 112,998 shares while in the previous session number of ABOS shares traded was 113,384 . The average number of ABOS shares traded daily for last 3 months was 235.98 Thousands.
The percentage change in ABOS stock occurred in the recent session was 15.79% while the dollar amount for the price change in ABOS stock was $0.75.
In the recent session, the day high for ABOS stock was $5.5 while the low for ABOS stock touched on the day was $4.659.
The market value of ABOS currently stands at 222.31 Million with its latest stock price at $5.5 and 40.47 Million of its shares outstanding.